[go: up one dir, main page]

NO20043085L - Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet - Google Patents

Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet

Info

Publication number
NO20043085L
NO20043085L NO20043085A NO20043085A NO20043085L NO 20043085 L NO20043085 L NO 20043085L NO 20043085 A NO20043085 A NO 20043085A NO 20043085 A NO20043085 A NO 20043085A NO 20043085 L NO20043085 L NO 20043085L
Authority
NO
Norway
Prior art keywords
compositions
treatment
methods
nervous system
central nervous
Prior art date
Application number
NO20043085A
Other languages
English (en)
Inventor
Merouane Bencherif
Mario B Marrero
Original Assignee
Med College Georgia Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Med College Georgia Res Inst filed Critical Med College Georgia Res Inst
Publication of NO20043085L publication Critical patent/NO20043085L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/946—CNS-stimulants, e.g. cocaine, amphetamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
NO20043085A 2001-12-14 2004-07-13 Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet NO20043085L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34058201P 2001-12-14 2001-12-14
US36993402P 2002-04-04 2002-04-04
PCT/US2002/039952 WO2003051302A2 (en) 2001-12-14 2002-12-13 Methods and compositions for treatment of central nervous system disorders

Publications (1)

Publication Number Publication Date
NO20043085L true NO20043085L (no) 2004-07-13

Family

ID=26992172

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043085A NO20043085L (no) 2001-12-14 2004-07-13 Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet

Country Status (13)

Country Link
US (2) US7067261B2 (no)
EP (1) EP1463481A4 (no)
JP (1) JP2005538683A (no)
CN (1) CN100371714C (no)
AU (1) AU2002360598B2 (no)
BR (1) BR0214929A (no)
CA (1) CA2470567A1 (no)
HU (1) HUP0501017A3 (no)
IL (1) IL162153A0 (no)
NO (1) NO20043085L (no)
NZ (2) NZ554913A (no)
PL (1) PL374384A1 (no)
WO (1) WO2003051302A2 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
CA2575706A1 (en) * 2004-08-02 2006-02-23 Bebaas, Inc. Vitamin b12 compositions
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
NZ555334A (en) 2004-12-24 2010-05-28 Spinifex Pharm Pty Ltd Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist
WO2006114019A1 (en) * 2005-04-26 2006-11-02 Versitech Limited Polysaccharide extract from lycium barbarum as neuroprotective agent against beta-amyloid peptide neurotoxicity
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
US20070178141A1 (en) * 2005-09-07 2007-08-02 Bebaas, Inc. Vitamin B12 compositions
AU2007229322B2 (en) * 2006-03-20 2012-04-05 Novartis Ag Method of treatment or prophylaxis inflammatory pain
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
CN101528698A (zh) 2006-05-09 2009-09-09 阿斯利康公司 (2s)-(4e)-n-甲基-5-[3-(5-异丙氧基吡啶)基]-4-戊烯-2-胺的盐形式
JP5153114B2 (ja) 2006-10-12 2013-02-27 知宏 千葉 新規のアルツハイマー病検出方法
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
CA2669088C (en) * 2006-11-10 2016-04-05 Dimerix Bioscience Pty Ltd Detection system and uses therefor
EP2112923A1 (en) * 2007-01-22 2009-11-04 Targacept Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
WO2008109517A1 (en) * 2007-03-02 2008-09-12 University Of South Florida Neurodegenerative disease treatment using jak/stat inhibition
WO2010056622A1 (en) * 2008-11-11 2010-05-20 Targacept, Inc. TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS
SI2889033T1 (en) 2008-11-19 2018-08-31 Forum Pharmaceuticals Inc. Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
WO2010132423A1 (en) * 2009-05-11 2010-11-18 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
CN103221411B (zh) 2010-05-17 2016-05-11 富瑞姆制药公司 (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型
JP2013528601A (ja) 2010-05-20 2013-07-11 アストラゼネカ・アクチエボラーグ アリール置換オレフィン系アミンの新規な製造方法
CN106074548A (zh) 2010-09-23 2016-11-09 艾伯维巴哈马有限公司 氮杂金刚烷衍生物的一水合物
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
WO2015189342A1 (en) * 2014-06-13 2015-12-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions comprising an at2r agonist for treating pain
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
EP4433053A4 (en) * 2021-11-17 2025-09-17 Lenz Therapeutics Operations Inc ACECLIDINE DERIVATIVES, THEIR COMPOSITIONS AND METHODS OF USE
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0216357A3 (en) 1985-09-25 1988-08-31 Nippon Zeon Co., Ltd. Phosphoramidite compounds and process for production thereof
US4922901A (en) * 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US6440681B1 (en) * 1990-04-03 2002-08-27 Merck & Co., Inc. Methods for identifying agonists and antagonists for human neuronal nicotinic acetylcholine receptors
US5369028A (en) * 1990-04-03 1994-11-29 The Salk Institute Biotechnology/Industrial Associates, Inc. DNA and mRNA encoding human neuronal nicotinic acetylcholine receptor compositions and cells transformed with same
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5837815A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polypeptide products
US5604231A (en) * 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5712270A (en) * 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
WO1999066041A1 (en) * 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 human secreted proteins
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
US5986100A (en) * 1998-04-02 1999-11-16 Crooks; Peter Anthony Pharmaceutical compositions and methods for use
US6057446A (en) * 1998-04-02 2000-05-02 Crooks; Peter Anthony Certain 1-aza-tricyclo [3.3.1-13,7 ] decane compounds
US5952339A (en) * 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
US6277870B1 (en) * 1998-05-04 2001-08-21 Astra Ab Use
DK1083889T3 (da) 1998-06-01 2004-04-13 Ortho Mcneil Pharm Inc Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme
US6232316B1 (en) * 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
ATE273956T1 (de) 1998-06-16 2004-09-15 Targacept Inc Arylsubstituierte olefinische amine und ihre verwendung als cholinergische rezeptoragonisten
US6218383B1 (en) * 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6262124B1 (en) * 1998-10-22 2001-07-17 Gary Maurice Dull Pharmaceutical compositions and methods for use
EP1185513A2 (en) 1999-05-24 2002-03-13 Targacept, Inc. Aryl substituted alkylamines capable of activating nicotinic cholinergic receptors
US20020052311A1 (en) * 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US6376242B1 (en) * 1999-09-21 2002-04-23 Emory University Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
WO2001082978A2 (en) 2000-05-01 2001-11-08 Targacept, Inc. Imaging of nicotinic acetylcholine receptor subtypes
US6852721B2 (en) 2000-05-25 2005-02-08 Targacept, Inc. Pharmaceutical compositions and methods for use
US6440970B1 (en) * 2000-05-25 2002-08-27 Targacept, Inc. Pharmaceutical compositions and methods for use
EA005520B1 (ru) 2000-06-27 2005-04-28 Лабораториос С.А.Л.В.А.Т.,С.А. Карбаматы, полученные из арилалкиламинов
EP1381603A2 (en) 2000-08-18 2004-01-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
US6492386B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
JP2004506734A (ja) 2000-08-21 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用のキヌクリド置換ヘテロアリール部分
US6500840B2 (en) 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002015662A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
KR100869722B1 (ko) 2000-12-22 2008-11-21 알미랄 에이쥐 퀴누클리딘 카르바메이트 유도체 및 ｍ3 길항제로서 그의사용

Also Published As

Publication number Publication date
NZ554913A (en) 2009-01-31
WO2003051302A2 (en) 2003-06-26
HUP0501017A2 (en) 2006-01-30
NZ533259A (en) 2007-10-26
AU2002360598A1 (en) 2003-06-30
AU2002360598B2 (en) 2008-02-14
JP2005538683A (ja) 2005-12-22
IL162153A0 (en) 2005-11-20
CN1605027A (zh) 2005-04-06
US20060160835A1 (en) 2006-07-20
CA2470567A1 (en) 2003-06-26
HUP0501017A3 (en) 2010-06-28
BR0214929A (pt) 2006-05-30
PL374384A1 (en) 2005-10-17
EP1463481A2 (en) 2004-10-06
WO2003051302A3 (en) 2003-09-04
US7067261B2 (en) 2006-06-27
CN100371714C (zh) 2008-02-27
US20030158211A1 (en) 2003-08-21
EP1463481A4 (en) 2008-06-25

Similar Documents

Publication Publication Date Title
NO20043085L (no) Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
NO20040097L (no) Kombinasjoner for behandling av inflammatoriske forstyrrelser
EP1471909A4 (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
NO20043237L (no) Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser
NO20034056D0 (no) Proliferative sykdommer
NO20041386L (no) Kombinasjoner for bahandling av immunoinflammatoriske forstyrrelser
IL157734A0 (en) Pharmaceutical compositions for the treatment of urogenital disorders
EE200100441A (et) Monoamiinide taasomastamise inhibiitorid kesknärvisüsteemi haiguste raviks
AU2003249983A8 (en) Piperidines useful for the treatment of central nervous system disorders
PT2266594E (pt) Vegf para utilização no tratamento de distúrbios do sistema nervoso central
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
SI1627639T1 (sl) Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj
DK1339406T3 (da) Piperazinderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af lidelser i centralnervesystemet
DE60218451D1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
EP1491212A4 (en) REMEDY AGAINST SLEEP DISORDERS
EP1478438A4 (en) TECHNIQUES AND COMPOSITIONS FOR THE TREATMENT OF ASTHMA AND RELATED DISORDERS
NO20023448D0 (no) Medikamentkombinasjon for behandling av depresjon og beslektede forstyrrelser omfattende mirtazapin
NO20054913D0 (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
AU2002362115A8 (en) Composition and methods for treatment of neurological disorders
NO20032156D0 (no) Behandling av angstforstyrrelser
NO20010390D0 (no) Behandling av angstsykdommer
IL176453A0 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
NO20052264D0 (no) Pregahalinderivater for behandling av fibromyalgi og andre forstyrrelser
NO20043113L (no) Fremgangsmate for behandling av benforstyrrelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application